Recent advances in the treatment of rhinovirus infections

Current Opinion in Pharmacology

Volumn 1, Issue 5, 2001, Pages 477-481

  McKinlay, Mark A ^a  

^a ViroPharma Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PROTEIN SYNTHESIS INHIBITOR; VIRUS PROTEIN; VIRUS RECEPTOR;

ANIMAL; BIOSYNTHESIS; DRUG EFFECT; HUMAN; PHYSIOLOGY; PICORNAVIRUS INFECTION; REVIEW; RHINOVIRUS; VIRION; VIROLOGY; VIRUS CAPSID;

ANIMAL; ANTIVIRAL AGENTS; CAPSID; HUMAN; PICORNAVIRIDAE INFECTIONS; PROTEIN SYNTHESIS INHIBITORS; RECEPTORS, VIRUS; RHINOVIRUS; VIRAL PROTEINS; VIRION;

EID: 0035491950     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(01)00083-2     Document Type: Review

References (26)

1. Benson V, Marano MA: Current estimates from the National Health Interview Survey, 1995. Vital Health Stat 1998, 10:199.
2. Turner RB: The common cold. Pediatr Ann 1998, 27:790-795.
3. Turner RB: The treatment of rhinovirus infections: progress and potential. Antiviral Res 2001, 49:1-14. A summary of the pathogenesis of rhinovirus infections, advances in symptomatic treatment and potential new treatment targets.
4. Rotbart HA, Hayden FG: Picornavirus infections: a primer for the practitioner. Arch Fam Med 2000, 9:913-922. A summary of the pathogenesis, clinical manifestations, diagnosis and treatment of diseases caused by the rhinoviruses and enteroviruses.
5. Centers for Disease Control: National Center for Health Statistics. Common cold FastStats. Vital Health Stat 1996, 10:200.
6. McKinlay MA, Pevear DC, Rossman MG: Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment. Annu Rev Microbiol 1992, 46:635-645.
7. Munoz FM, Galasso GJ, Gwaltney JM Jr, Hayden FG, Murphy B, Webster R, Wright P, Couch RB: Current research on influenza and other respiratory viruses: II International Symposium. Antiviral Res 2000, 46:91-124.
8. Diana GD, Pevear DC: Antipicornavirus drugs: current status. Antiviral Chem Chemother 1997, 8:401-408.
9. Rotbart HA: Review: antiviral therapy for enteroviruses and rhinoviruses. Antiviral Chem Chemother 2000, 11:261-271. A review of the history, current status and prospects for agents to treat rhinovirus and enterovirus infections.
10. Turner RB, Wecker MT, Pohl G, Witek TJ, McNally E, St George R, Winther B, Hayden FG: Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. J Am Med Assoc 1999, 281:1797-1804.
11. Kaiser L, Crump CE, Hayden FG: In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. Antiviral Res 2000, 47:215-220. An assessment of the in vitro activity of two antipicornavirus agents with different mechanisms of action on a group of clinical rhinovirus isolates.
12. Schmidt AC, Couch RB, Galasso GJ, Hayden FG, Mills J, Murphy BR, Chanock RN: Current research on respiratory viral infections Third International Symposium. Antiviral Res 2001, 50:157-196.
13. Smith TJ, Kremer MJ, Luo M, Vriend G, Arnold E, Kamer G, Rossmann MG, McKinlay MA, Diana G D, Otto MJ: The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science 1986, 233:1286-1293.
14. Pevear DC, Fancher MJ, Felock PJ, Rossmann MG, Miller MS, Diana G, Treasurywala AM, McKinlay MA, Dutko FJ: Conformational changes in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors. J Virol 1989, 63:2002-2007.
15. Abdel-Rahman SM, Kearns GL: Single oral dose escalation pharmacokinetics of pleconaril (VP 63843) capsules in adults. J Clin Pharmacol 1999, 39:613-618.
16. Watson KG, Wu WY, Krippner GY, McConnell DB, Jin B, Stanislawski PC, Brown RN, Chalmers DK, Tucker SP, Cameron-Smith R et al.: A new class of capsid-binder with potent inhibitory activity against rhinovirus in cell culture [abstract]. Antiviral Res 2001, 50:A75.
17. Hayden FG, Crump C, Reece PA, Watson K, Ryan J, Cameron-Smith R, Tucker SP: In vitro anti-rhinovirus spectrum and potency of BTA188, novel, oral picornavirus capsid-binder [abstract]. Antiviral Res 2001, 50:A75.
18. Ryan J, Sidwell RW, Barnard D, Tucker SP, Reece PA: Preclinical pharmacokinetics of a new rhinovirus inhibitor, BTA188 [abstract]. Antiviral Res 2001, 50:A76.
19. Pevear DC, Tull TM, Seipel ME, Groarke JM: Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother 1999, 43:2109-2115.
20. Kearns GL, Bradley JS, Jacobs RF, Capparelli EV, James LP, Johnson KM, Abdel-Rahman SM: Single dose pharmacokinetics of pleconaril in neonates. Pediatr Infect Dis J 2000, 19:833-839.
21. Kearns GL, Abdel-Rahman SM, James LP, Blowey DL, Marshall JD, Wells TG, Jacobs RF: Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution in children and adolescents. Antimicrob Agents Chemother 1999, 43:634-638.
22. th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1999 September 26-29, San Francisco.
23. Hayden FG, Kim K, Coats T, Blatter M, Drehobl: Pleconaril treatment shortens duration of picornaviral upper respiratory illness in adults. Abstract H1161 of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2000 September 17-20, Toronto, Canada.
24. Hayden FG, Kim K, Hudson S: Pleconaril treatment reduces duration and severity of viral respiratory infection (common cold) due to picomaviruses. Pleconaril Respiratory Infection Study Group. Abstract 44 of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, 2001 September 22-25, Chicago.
25. Rotbart HA, Liu S: Cumulative safety of pleconaril: a novel antiviral. Abstract IDSA-201930 of the 39th Annual Conference of the Infectious Disease Society of America, 2001 October 25-28, San Francisco.
26. Rotbart HA: Enteroviruses: overview of treatments, current and future. Infect Med 1999, 16(suppl D):27-32.